Lauren Smith
Family Medicine · Ionia, MINPI 1649290685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $633, 2.5 times the $250 reported in 2019.
Across 132 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$390
- Pfizer$330
- AbbVie$211
- AstraZeneca$185
- Stryker$158
- Otsuka America Pharmaceutical, Inc.$135
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,57799%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $390 |
| Pfizer | 22 | $330 |
| AbbVie | 11 | $211 |
| AstraZeneca | 12 | $185 |
| Stryker | 1 | $158 |
| Otsuka America Pharmaceutical, Inc. | 7 | $135 |
| Dexcom, Inc. | 6 | $130 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Boehringer Ingelheim | 5 | $105 |
| Organogenesis Inc. | 1 | $98 |
| GSK | 5 | $95 |
| Amgen | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $73 |
| Exact Sciences | 4 | $66 |
| Astellas Pharma US Inc | 3 | $66 |
| Lilly USA, LLC | 3 | $53 |
| Lundbeck LLC | 2 | $47 |
| Merck | 2 | $46 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Cranial Technologies, Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VARIAX$158
How this compares
$2,596 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $90,584 |
| EliquisApixaban | 67 | $75,429 |
| JanuviaSitagliptin Phosphate | 52 | $70,631 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $27,247 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $26,974 |
| XareltoRivaroxaban | 24 | $25,752 |
| MounjaroTirzepatide | 24 | $24,121 |
| Spiriva HandihalerTiotropium Bromide | 22 | $21,607 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $10,789 |
| MyrbetriqMirabegron | 18 | $10,320 |
| Tiotropium Bromide | 11 | $9,461 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $9,047 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $7,726 |
| Atorvastatin Calcium | 433 | $6,052 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $6,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $105 | $117,83197 claims |
| PfizerEliquis, Premarin | $330 | $81,14379 claims |
| MerckJanuvia | $46 | $70,63152 claims |
| Johnson & JohnsonXarelto | $13 | $25,75224 claims |
| Lilly USA, LLCMounjaro | $53 | $24,12124 claims |
| Astellas Pharma US IncMyrbetriq | $66 | $10,32018 claims |
| AstraZenecaSymbicort | $185 | $7,72614 claims |
| Novo NordiskNovolog Mix 70-30 | $390 | $3,16716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Ionia
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.